CYP19A1 and fatty liver disease: An animal study using the aromatase-knockout mouse showed that hepatic steatosis developed in aromatase-deficient mice [25, 26], and estradiol replacement therapy reversed hepatic steatosis, suggesting a role for estrogen in maintaining lipid homeostasis in the liver [27].